Abstract:To the Editor: Cervical cancer ranks the fourth cause of cancer mortality in women worldwide.1 Neoadjuvant chemotherapy has remarkable effects on advanced cervical cancer,2 but 15%–34% of patients do not respond to drug treatment.3 Using the integrated analysis of whole-exome sequencing (WES) and CRISPR screening, our data explored the intrinsic mechanisms that contribute to chemoresistance. We performed WES analysis on 135 cervical cancer patients who were classified as responders or nonresponders to neoadjuvant chemotherapy from our previous research4 (Figure 1). A total of 38 884 somatic mutations and 13 058 nonsynonymous mutations were detected. Sixty significant copy number variation (CNV) events (19 amplifications, 41 deletions) were identified in 89 tumour samples (Figure 2A and Data S1). Among them, eight CNV events (five amplifications, three deletions) had higher frequencies in drug-resistant patients' group, including 3q26.31 (amplification; odds ratio [OR] = 2.18, p = .047), 3q29 (amplification; OR = 2.25, p = .032), 4p16.1 (deletion; OR = 2.58, p = .012), 8p23.1 (deletion; OR = 2.62, p = .0096), 12q13.3 (amplification; OR = 4.59, p = .00067), 14q11.2 (amplification; OR = 2.66, p = .022), 19q13.31 (amplification; OR = 2.64, p = .021) and 22q11.21 (deletion; OR = 3.25, p = .0018) (Figure 2A and Data S2). Here ORs were the ratio of the odds of treatment response in the presence of CNV and the odds of treatment response in the absence of CNV. Seven thousand ninety-two mutated genes were detected in 102 samples (102/135, 75.56%), with 21 driver genes identified.5,6 Six were reported driver genes in previous study,7,8 including PIK3CA (n = 23, 17.03%), CASP8 (n = 13, 9.62%), EP300 (n = 11, 8.15%), FBXW7 (n = 10, 7.41%), STK11 (n = 6, 4.44%), and MAPK1 (n = 5, 3.7%). In addition, we identified 15 novel driver genes including TTN (n = 45, 33.33%), UBR4 (n = 16, 11.85%), ACPP (n = 9, 6.67%), BAP1 (n = 7, 5.19%), and FBXW10 (n = 7, 5.19%) (Figure 2B and Data S3). We obtained a drug-resistant gene set of 3163 genes, including 1978 genes mutated only in drug-resistant patients' group, and 1185 genes with higher mutation frequency in drug-resistant patients' group than in drug-sensitive patients' group (OR > 1) (Figure 2C,D). Among the 3163 clinical drug-resistant genes, there were 36 genes with significantly higher mutation frequencies (Data S4). Total 34 out of the 36 genes were only mutated in the drug-resistant group, the other two PLXNB2 (n = 7, 5.19%, OR = 12.07; p = .008) and SYNE1 (n = 11, 8.15%, OR = 5.52; p = .017) were mutated in both drug-resistant and -sensitive groups (Figure 2D). We checked PLXNB2, the gene with the most significant p-value, and found its mutations arising from drug-resistant patients were located in the C terminal or N terminal of the gene (Figure 2E). To integrate the genomic data with functional analysis, we carried out genome-scale CRISPR/Cas9 knockout library screening9 in HeLa and SiHa cells, which were incubated with cisplatin or paclitaxel, respectively (Figure 3A). The enriched sgRNAs were identified in the surviving cell population. Through this method, we identified 6625 drug-resistant genes, including 44.23% of genes only in HeLa and 40.9% of genes only in SiHa (Figure 3B). Ninety-seven genes not only ranked in the top 25% of all CRISPR screening resistance genes but also showed resistance to drugs in both HeLa and SiHa cells (Data S5–S7). One thousand seventy-four genes were identified by overlapping the 3163 clinical drug-resistant genes and the 6625 CRISPR library drug-resistant genes (Figure 3C), with 479 (43.86%) only in HeLa and 440 (40.29%) genes only in SiHa (Figure 3D). Of note, 17 out of 36 genes whose mutation frequencies were significantly higher in drug-resistant patients than in drug-sensitive patients (Data S4) also showed resistant property in CRISPR screening experiments (Figure 3E). To determine the biological processes affecting the outcome of chemotherapy, we performed GO enrichment analysis10 on the 1074 drug-resistant genes, 652 HeLa resistant genes, 613 SiHa resistant genes and 173 common resistant genes, respectively (Figure 3F,G). Double-strand break repair process was enriched in all resistant genes (gene ratio = 2.1%, p = .026) as well as in HeLa and SiHa common resistant genes (gene ratio = 5.6%, p = .00029). We noticed that HERC2 (OR = 5.53, p = .13), which participated in double-strand break repair (Figure 3F,G), was a drug-resistant gene to both cisplatin (HeLa + cisplatin + 7 days: p = .035, log2 fold change = 1.27) and paclitaxel (SiHa + paclitaxel + 14 days: p = .015, log2 fold change = 3.68) treatment (Figure 3H). Additionally, axon guidance process was enriched in both the total 1074 resistant genes (gene ratio = 2.87%; p = .0008) and 613 SiHa resistant genes (gene ratio = 3.72%; p = .00016) (Figure 3F,G). We found that plexin-B family genes played important roles in the axon guidance process. PLXNB1 was resistant to cisplatin in SiHa (cisplatin + 14 days: p = .018, log2 fold change = 7.63) and PLXNB2 was resistant to cisplatin in HeLa (cisplatin + 7 days: p = .018, log2 fold change = 1.3; cisplatin + 14 days: p = .048, log2 fold change = 3.48) (Figure 3H). In addition, KEGG enrichment analysis10 was performed on the 1074 integrated drug-resistant genes (Figure S1). Platinum drug resistance pathway (gene ratio = 3.28%; p = .0061), ubiquitin-mediated proteolysis (gene ratio = 5.57%; p = .0016), focal adhesion (gene ratio = 4.26%; p = .0042), MAPK signaling pathway (gene ratio = 8.52%; p = .01) and ABC transporters (gene ratio = 2.3%; p = .01) were closely related to treatment response for cervical cancer (Figure S1). To verify the roles of key genes PLXNB1 and HERC2, we further generated PLXNB1 and HERC2 knockdown SiHa cells by siRNAs (Figure S2). PLXNB1 knockdown SiHa cells showed higher viability in the presence of cisplatin and paclitaxel compared to controls (Figure 4A,B). HERC2 knockdown SiHa cells showed higher viability in the presence of cisplatin but not paclitaxel (Figure 4C,D). Together, the above data indicated that plexin-B family connected axon guidance to PI3K-Akt signaling as well as ErbB signaling pathways, which were closely associated with drug response and cell life (Figure 4E). In conclusion, by integrating the evidences from both clinical data and in vitro CRISPR screenings, this study achieved extensive exploration of the mechanisms for chemotherapy resistance in cervical cancer. We provided a novel strategy that not only identified a series of drug-resistant target genes but also exhibited comprehensive biological processes engaged in treatment responses. We thank the patients and their families who contributed to this research study. Application Foundation Frontier Project of Wuhan Science and Technology Bureau, Grant Number: 2020020601012324; National Natural Science Foundation of China, Grant Numbers: 81902663, 82172584, 32171465, and 82102392; Medical Research Project of Wuhan Municipal Health Commission, Grant Numbers: WZ18Q02, and WX21Q09; National Science and Technology Major Project of the Ministry of Science and Technology of China, Grant Number: 2018ZX10301402; General Program of Natural Science Foundation of Guangdong Province of China, Grant Number: 2021A1515012438; National Postdoctoral Program for Innovative Talent, Grant Number: BX20200398; China Postdoctoral Science Foundation, Grant Number: 2020M672995; Guangdong Basic and Applied Basic Research Foundation, Grant Number: 2020A1515110170; Characteristic Innovation Research Project of University Teachers, Grant Number: 2020SWYY07; National Ten Thousand Plan-Young Top Talents of China. The authors declare that there is no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:In a recent study published in Signal Transduction and Targeted Therapy, Zhang et al.1 identified a panel of genes that served as a novel predictor of response to poly adenosine diphosphate-ribose polymerase (PARP) inhibitors/cisplatin in HR proficient patients, which could guide a broader application of PARP inhibitors/cisplatin in cancer therapy. Cancer cells differ from normal cells in their ability to repair damaged DNA—most cancer cells lose one or more DNA repair pathways, resulting in greater reliance on the remaining pathways.2 Thus, small molecules that can induce DNA damage have been used to treat various cancers. Among them, cisplatin/PARP inhibitors are well established cancer drugs and are used to target tumor cells with homologous recombination (HR) defects.2 Platinum salts (carboplatin, cisplatin, and oxaliplatin) are the commonly-used chemotherapeutic agents, which were historically thought to cause cell death by inducing DNA damage.2 Recent studies suggest that the mechanisms of action of platinum salts are more diverse3 (Figure 1A). Zhang et al.1 further showed that cisplatin promotes cell death through DNA damage-induced ribosomal stress, rather than failed DNA repair, in certain tumor cells. PARP inhibitors are approved for the treatment of ovarian and breast cancers with BRCA1/2 mutations, and act through synthetic lethality in DNA repair-deficient tumors.3-5 However, it is known that some HR-proficient patients also respond well to PARP inhibitors and cisplatin therapy.3 Consistently, Zhang et al.1 also identified patients who benefited from the treatment of PARP inhibitors, despite their normal HR functions. Therefore, it is necessary to identify biomarkers that can help to stratify the patients so they will benefit most from PARP inhibitors and cisplatin therapy. To identify these biomarkers, the authors analyzed RNA-Seq data from the Cancer Cell Line Encyclopedia and drug sensitivity data (GDSC) from the extensive and Sanger cell line databases1 (Figure 1B). They used weighted gene co-expression network analysis to negatively correlate drug signatures with co-expressed gene modules.1 Through these analyses, the authors found that expression of genes in the ribosome biogenesis pathway could be used to predict cellular drug response to PARP inhibition or cisplatin-based chemotherapy.1 Ultimately, they obtained a panel of 8 genes involved in ribosome biogenesis for further analysis.1 In the following studies, the authors provided multiple lines of evidence suggesting that these eight genes could be used to predict PARP inhibitors/cisplatin sensitivity.1 First, HR-proficient tumor cell lines in which the eight genes were highly expressed were sensitive to PARP inhibitors.1 Second, the authors verified the results using an organoid library for ovarian cancer treated with PARP inhibitors/cisplatin.1 Finally, the authors collected a clinical cohort of PARP inhibitor-treated ovarian cancer patients and obtained similar results.1 Importantly, this may be the first clinical cohort with both complete patient RNA-Seq and WGS data for PARP inhibitor treatment.1 Based on these studies, the authors proposed a new paradigm to expand the clinical use of PARP inhibitors/cisplatin by combining the gene panel testing and HR status screening1 (Figure 1C). In 2005, Helladay and Ashwoth's groups discovered that mutation of BRCA1/2 disrupted the HR pathway of DNA repair in cells, and render the cancer cells particularly sensitive to inhibition of the enzyme PARP.4, 5 As PARP is involved in base excision repair, they proposed a synthetic lethal strategy by simultaneously blocking two DNA repair pathways.4, 5 Zhang et al.1 suggested that this model could only apply to cells with low expression of the eight genes; in cells with high expression, PARP inhibitors/cisplatin can induce cancer cell death independent of HR status. The new data explained why a large number of patients with normal HR functions are also sensitive to PARP inhibitors/cisplatin.1 More importantly, this study suggests that increasing the expression of the 8 genes may represent a novel synergistic lethal strategy, and the authors have already reported three marketed drugs with such functions.1 Many studies have focused on the DNA repair pathways to understand the sensitivity of PARP inhibitors/cisplatin treatment.2-5 Zhang et al.1 went a different direction by searching new features that could predict the response to PARP inhibitors/cisplatin treatment, and made several interesting findindings. First, they discovered a gene panel that could be used to predict PARP inhibitors/cisplatin response in HR proficient patients. In their newly proposed paradigm, patients with high expression of the eight genes could be screened out to undergo PARP inhibitors/cisplatin treatment.1 Compared to HR status testing, the gene panel testing could be much cheaper and convenient. Secondly, Zhang et al.1 proposed a new synthetic lethal strategy that is distinct from the classical strategy suggested by Helladay and Ashwoth's groups. Helladay and Ashwoth's strategy relies on inhibiting two different DNA repair pathways, but fails to explain why PARP inhibitor/cisplatin are still effective in treating many tumor patients with normal HR functions.1 Zhang et al.1 found that PARP inhibitor/cisplatin could induce lethality in cells with high expression of the eight genes, even their HR functions were proficient.1 As a result, they proposed a new therapeutic strategy by combining PARP inhibitor/cisplatin with drugs that increase the expression of the eight genes.1 Last but not least, the authors reported that three marketed drugs could enhance the treatment effect of PARP inhibitors/cisplatin in some tumor cells.1 Future studies should identity additional drugs with similar activities. Of course, their work also raises some important questions. First, more rigorous prospective trials are required to validate the authors' conclusions, due to the heterogeneity of ovarian cancer and inherent bias of the retrospective studies. Second, it remains to pinpoint the mechanisms by which these genes regulate ribosomal stress and thus affect cancer drug sensitivity.1, 2 In summary, the study by Zhang et al.1 represents a major milestone in the fields of DNA repair and cancer chemotherapy, and may stimulate additional works that search novel therapeutical approaches by targeting the DNA repair pathways. Jinrui Wang: writing—original draft (equal); writing—review & editing (equal). Daniel D. Billadeau: writing—original draft (equal); writing—review & editing (equal). Ying Zheng: writing—original draft (equal); writing—review & editing (equal). Da Jia: Funding acquisition (equal); writing—original draft (equal); writing—review & editing (equal). All authors have read and approved the final manuscript. Grant support from National Key Research and Development Program and National Natural Science Foundation of China (NSFC) is acknowledged. Research in the authors' laboratory is supported by National Key Research and Development Program of China (2022YFA1105200), National Natural Science Foundation of China (NSFC) grants (#92254302), National Science Fund for Distinguished Young Scholars (#32125012). The authors declare no conflicts of interest. This study did not involve human participants and/or animals or informed consent. Thus, ethical clearance is not applicable to this article. No datasets were generated or analyzed during the current study. Thus, data sharing is not applicable to this article.

Somatic Mutations and CRISPR/Cas9 Library Screening Integrated Analysis Identifies Cervical Cancer Drug‐resistant Pathways

Abstract P2-23-01: Patient-derived Xenografts Allow Deconvolution of Single Agent and Combination Chemotherapy Responses in Triple-Negative Breast Cancer

A New Synthetic Lethal Strategy Expands the Application of PARP Inhibitors/cisplatin

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Abstract 5664: Genetic alterations and pharmacological response profiles from 10 cervical cancer cell lines

Global Analysis of DNA Methylation by Methyl-Capture Sequencing Reveals Epigenetic Control of Cisplatin Resistance in Ovarian Cancer Cell.

Overexpression of SMARCA2 or CAMK2D is Associated with Cisplatin Resistance in Human Epithelial Ovarian Cancer

Abstract 543: Identifying drivers of chemoresistance in SQLC using forward and reverse genetic approaches

CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

Abstract A035: Genome-wide CRISPRi screening reveals determinants of platinum sensitivity and resistance in high-grade serous ovarian cancer

Single-Cell RNA Sequencing Reveals Multiple Pathways and the Tumor Microenvironment Could Lead to Chemotherapy Resistance in Cervical Cancer

Abstract PO1-14-08: Real-world clinical genomics study of HR+/HER2- metastatic breast cancers treated by CDK4/6i plus endocrine therapies revealed a drug resistant tumor segment characterized by ER independence

Abstract PR06: CRISPR Screens Identified Drivers of Endocrine Resistance and Synthetic Lethal Vulnerabilities in Breast Cancer

A Genome Wide CRISPR Profiling Approach Identifies Mechanisms of Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma.

Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer

The Genomic Signature of Resistance to Platinum-Containing Neoadjuvant Therapy Based on Single-Cell Data

A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery

Genome-scale CRISPR Activation Screening Identifies a Role of ELAVL2-CDKN1A Axis in Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma.

Abstract 544: Reverse engineering strategy for new targets identification

Abstract 571: CRISPR/Cas9 screening identifies the proteasome subunit PSMC6 as key for the survival of cisplatin-resistant ovarian carcinoma cells